Table of Contents

Technology in Digital Diabetes Management Market

Digital diabetes management market is projected to reach USD 35.8 Billion by 2028 from an estimated USD 18.9 Billion in 2023, at a CAGR of 13.6%
Digital diabetes management market

The global digital diabetes management market is experiencing meteoric growth, projected to soar from $18.9 billion in 2023 to a staggering $35.8 billion by 2028, at a compound annual growth rate (CAGR) of 13.6%. This burgeoning industry is driven by the ever-increasing prevalence of diabetes worldwide and the corresponding demand for innovative, technologically advanced solutions to manage this chronic condition effectively.

Spearheading this revolution are groundbreaking advancements in artificial intelligence (AI) and connected devices. AI algorithms are revolutionizing diabetes care, enabling predictive models for risk assessment, optimizing resource utilization, and enhancing glycemic control. Pioneers like Medtronic, Abbott, and Dexcom are at the forefront of this AI-powered transformation, introducing cutting-edge devices such as artificial pancreas systems, continuous glucose monitoring (CGM) systems, and smart insulin pumps.

Download a PDF Brochure:

However, the high costs of these advanced devices and the lack of reimbursement policies in developing countries remain significant barriers to widespread adoption. With prices ranging from $4,500 to $6,500 for insulin pumps and $1,000 to $1,400 for CGM systems, these solutions remain out of reach for many patients, particularly in low-income regions.

Despite these challenges, the escalating global health expenditure due to diabetes presents a compelling opportunity for market growth. The International Diabetes Federation (IDF) estimates that diabetes-related health expenditure will reach a staggering $1.03 trillion by 2030, representing a substantial 11.5% of total global health spending.

The market landscape is dominated by prominent players like Medtronic, B. Braun Melsungen AG, Dexcom, Abbott Laboratories, F. Hoffmann-La Roche, Insulet Corporation, and Tandem Diabetes Care, among others. These companies are at the forefront of innovation, leveraging state-of-the-art technologies, diversified product portfolios, and robust global networks to drive market penetration.

Dexcom, Inc. (US)

In 2022, Dexcom was the market leader for digital diabetes management. With its flagship Dexcom products, the company dominated the market for continuous glucose monitoring systems. CGM systems like the Dexcom G7 and Integrated Continuous Glucose Monitoring (iCGM) System, Dexcom G6 Continuous Glucose Monitoring (CGM) System, Dexcom G5 Mobile CGM System, and Dexcom One are among the company’s product offerings. Company has 242 manufacturing and distribution facilities located all over the world. To increase its market share in digital diabetes management, Dexcom focuses on alliances, contracts, and acquisitions. Dexcom has partnered with a number of businesses in recent years to integrate its CGM system with additional insulin pumps. The company emphasises on growing its presence across the world, which gives it access to more resources for production and better customer service. For instance, the company established new offices in Scotland and Canada. The company also grew its footprint in additional regions, including Europe, Australia, the Middle East, and Africa.

Medtronic (Ireland)

The company’s broad product portfolio, which includes insulin pumps, smart glucose metres, CGM systems, mobile applications, data management software, and services, has been associated with its leading position in this market. The business is present throughout the world, including North America, Latin America, Europe, Africa, the Middle East, and Asia Pacific. MiniMed 780 Systems, MiniMed 670 Systems, Guardian Connect CGM Systems, CareLinkdiabetes Personal Software, and StartRight Programmes are all part of Medtronic’s digital portfolio for managing diabetes. The company emphasises on product launching, innovative products and establishing partnerships and alliances with other market participants in order to maintain its leading position in the market.

Abbott Laboratories (US)

In 2022, Abbott Laboratories held the third-position in the market for digital diabetes management. The company provides CGM systems, smart insulin pens, smart insulin pumps, smart insulin patches, and data management software. It also offers connected glucose metres. Abbott provides a range of digital CGM devices for managing diabetes and software platforms that are popular with end users all over the world under its flagship brand, freestyle libre. The geographic reach of Abbott Laboratories also extends to the Middle East, Africa, Asia, and North America. To keep up its market dominance, the company mainly focuses on product launches and alliances and collaborations. In October 2022, the company launched freestyle libre 3 CGM that has contributed significantly in its revenue.

Looking ahead, the smart insulin pen segment is poised for the highest growth, fueled by increasing demand for personalized and patient-centric devices, as well as the need to prevent needle-stick injuries. Additionally, the digital diabetes management apps segment is projected to experience rapid expansion, with diabetes and blood glucose tracking apps leading the charge.

As the digital diabetes management market continues its upward trajectory, it holds the promise of transforming diabetes care, empowering patients with cutting-edge solutions, and ultimately improving outcomes for millions of individuals affected by this chronic condition worldwide.

Blog Tags
Blog Category

Leave a Reply